Infinitopes

Executive Summary

Infinitopes is a UK-based biotechnology company spun out of Oxford University in 2021, dedicated to developing precision cancer vaccines. By integrating proprietary antigen discovery and vector platforms, the company aims to target the right antigens, deliver them with optimal vectors, to the right patients, at the right time. Its mission is to cure cancer through a personalized immunotherapy approach. The company has advanced to Phase 1/2 clinical trials, with a First-in-Human study initiated in 2024. Infinitopes' technology addresses key challenges in cancer vaccine development, including antigen selection and immune activation, positioning it as a promising player in the immuno-oncology space. With a strong scientific foundation from Oxford, the company is poised to generate initial clinical data that could validate its platform and attract strategic partnerships or additional funding. The precision oncology market is rapidly expanding, and Infinitopes' differentiated approach could capture significant value if clinical proof-of-concept is achieved.

Upcoming Catalysts (preview)

• H2 2026Phase 1 Interim Safety and Immunogenicity Data70% success
• 2026Announcement of Strategic Partnership or Licensing Deal40% success
• Q4 2026Completion of Phase 1 Enrollment and Transition to Phase 280% success